International Journal of Hematology and Oncology 2023, Vol 33, Num 4 Page(s): 141-144
FONDAPARINUX TREATMENT IN HEPARIN INDUCED THROMBOCYTOPENIA: CASE REPORT

Tülin AKAGÜN1, Mehmet SÖNMEZ2, Mustafa YILMAZ2, Elif AKDOĞAN2, Ahmet DURMUŞ2, Ercüment OVALI2, Serdar B. OMAY2

1Karadeniz Teknik Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, TRABZON
2Karadeniz Teknik Üniversitesi Tıp Fakültesi, Hematoloji Bilim Dalı, TRABZON

Keywords: HİT, Fondaparinux
Heparin induced thrombocytopenia (HIT) is a complication of heparin therapy, that is associated with thrombocytopenia, arterial and venous thromboembolism. HIT usually develops 5 and 14 days after commencement of heparin therapy. HIT is a situation that has high mortality if it is not treated. When HIT is suspected, all forms of heparin should be discontinued and treatment with a direct thrombin inhibitor should be initiated. Fondaparinux is a synthetic pentasaccharide anticoagulant drug which is used for the treatment of HIT. Our case represents thrombocytopenia / thrombosis as a complication of heparin therapy. We tried to make an overview of new treatment choices.